Data from the largest Danish MS center supports previous observations of unusual, long-lasting and unpredictable courses of alemtuzumab-induced GD. Thus, follow-up of these patients may require long lasting and more frequent biochemical measurements compared to other patients with GD. Also, concomitant block and replace treatment or definitive treatment, such as thyroidectomy, should be considered in a subgroup of patients.
Keyphrases
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- high glucose
- randomized controlled trial
- clinical trial
- machine learning
- oxidative stress
- radiation therapy
- drug induced
- big data
- endothelial cells
- combination therapy
- electronic health record
- deep learning
- artificial intelligence
- phase iii